What medication plan would you recommend for an 81‑year‑old female with anxiety and panic attacks who is taking alprazolam (Xanax) 0.5 mg twice daily and paroxetine (Paxil) 20 mg twice daily and wishes to taper off alprazolam because of falls and balance problems?

Medication Plan for Benzodiazepine Taper in an 81-Year-Old with Falls

Initiate a gradual alprazolam taper at 10% of the current dose per month while maintaining paroxetine 20 mg twice daily, integrating cognitive-behavioral therapy, and adding gabapentin 100–300 mg at bedtime to mitigate withdrawal symptoms.

---

Critical Safety Framework

Abrupt discontinuation of alprazolam after chronic use can cause seizures and death—never stop suddenly. 1 The taper rate must be determined by your patient's tolerance to withdrawal symptoms, not by a rigid schedule, and pauses are acceptable when symptoms emerge. 1

For an 81-year-old woman, benzodiazepines pose particularly high risks: cognitive impairment, falls, fractures, reduced mobility, and loss of functional independence. 1 The American Geriatrics Society Beers Criteria explicitly recommend avoiding all benzodiazepines in older adults due to these substantial risks. 1 Your patient's fall and balance issues are direct indications to discontinue alprazolam.

---

Recommended Tapering Protocol

Month-by-Month Reduction Schedule

Start with a 10% reduction of the current dose each month, not the original dose. 1 This prevents disproportionately large final reductions that occur when calculating from the starting dose. 1

• Current dose: Alprazolam 0.5 mg twice daily = 1.0 mg/day total
• Month 1: Reduce to 0.9 mg/day (10% reduction) — split as 0.45 mg twice daily
• Month 2: Reduce to 0.81 mg/day (10% of 0.9 mg) — split as 0.4 mg twice daily
• Month 3: Reduce to 0.73 mg/day (10% of 0.81 mg) — split as 0.35 mg twice daily
• Continue this pattern 1

For patients on benzodiazepines longer than one year, extending the taper to 10% per month is safer than faster schedules. 1 Expect a minimum timeline of 12–18 months for complete discontinuation. 1

When to Pause the Taper

Clinically significant withdrawal symptoms signal the need to slow or pause the taper entirely. 1 These include:

• Severe anxiety, panic attacks, or tremor 1
• Insomnia, sweating, tachycardia 1
• Headache, weakness, muscle aches, nausea 1
• Confusion, altered mental status, or seizures 1

When a pause is required, maintain the current dose for 2–4 weeks while optimizing non-pharmacologic therapies and adjunctive medications before resuming. 1

---

Maintain Baseline Anxiolytic Therapy

Keep paroxetine 20 mg twice daily stable throughout the entire taper. 1 Do not adjust the SSRI dose for anxiety symptoms that emerge during benzodiazepine withdrawal—these are expected withdrawal phenomena, not treatment failure. 1

Paroxetine is appropriate for long-term panic disorder management and should be continued for at least one year after symptom remission. 2 However, note that paroxetine is associated with discontinuation syndrome if it is stopped abruptly, so any future adjustment of paroxetine must also be gradual. 3

Common pitfall: Providers sometimes add new psychotropic medications during a benzodiazepine taper when symptoms worsen. Avoid this unless symptoms are unmanageable—most withdrawal symptoms resolve as the taper progresses. 1

---

Add Adjunctive Pharmacologic Support

Gabapentin for Withdrawal Symptom Mitigation

Start gabapentin 100–300 mg at bedtime or three times daily, increasing by 100–300 mg every 1–7 days as tolerated. 1 Gabapentin can help mitigate withdrawal symptoms including anxiety, insomnia, and muscle aches during benzodiazepine tapering. 1

• Titrate cautiously to avoid dose-dependent dizziness and sedation 1
• Adjust dosage in renal insufficiency 1
• Typical effective range: 300–900 mg/day in divided doses 1

For Insomnia During Taper

If sleep disturbance becomes problematic, consider low-dose doxepin 3–6 mg at bedtime as first-line. 1 This agent has minimal anticholinergic activity, no abuse potential, and is not a controlled substance—making it especially suitable for older adults discontinuing benzodiazepines. 1

Avoid trazodone in this 81-year-old patient: the American Academy of Sleep Medicine advises against trazodone for insomnia in older adults because it yields only ~10 minutes reduction in sleep latency, does not improve subjective sleep quality, and produces adverse events in roughly 75% of this population. 1

---

Integrate Cognitive-Behavioral Therapy

Incorporating CBT during the benzodiazepine taper significantly increases success rates and should be part of your treatment plan. 1 CBT targeting avoidance behaviors (e.g., skipping events, reliance on benzodiazepines for anticipated anxiety) improves taper success and reduces relapse risk. 1

Additional supportive measures include:

• Mindfulness and relaxation techniques 1
• Sleep hygiene education 1
• Exercise and fitness training 1
• Patient education about benzodiazepine risks and benefits of tapering 1

Evidence from controlled trials: Reduction in the fear of anxiety symptoms (anxiety sensitivity) was the single best predictor of patients' ability to achieve and maintain drug abstinence, correctly predicting outcome in 85% of cases. 4 CBT directly addresses this mechanism.

---

Monitoring Requirements

Follow up at least monthly during the taper, with more frequent contact during difficult phases. 1 At each visit:

• Verify adherence to paroxetine and gabapentin 1
• Assess withdrawal symptoms and their severity 1
• Screen for depression, anxiety, and suicidal ideation 1
• Monitor for falls, sedation, delirium, and respiratory compromise 1
• Check that alprazolam use is limited to the prescribed taper dose, not as-needed escalation 1

Multidisciplinary team members (nurses, pharmacists, behavioral health professionals) can provide additional support via telephone, telehealth, or in-person visits. 1

---

When to Refer to a Specialist

Immediate specialist referral is indicated if: 1

• History of withdrawal seizures or severe withdrawal reactions
• Unstable psychiatric comorbidities
• Co-occurring substance use disorders
• Previous unsuccessful office-based tapering attempts
• Concerns about managing complex polypharmacy

For this 81-year-old patient with falls and balance issues, if the taper proves unsuccessful or if cognitive impairment worsens during the taper, consider geriatric psychiatry consultation. 1

---

Expected Outcomes and Realistic Goals

Both complete discontinuation of alprazolam and attainment of a reduced, functionally acceptable dose are considered acceptable outcomes. 1 The goal is durability of the taper, not speed. 1

Maintenance therapy is a legitimate outcome for patients who cannot complete tapering. 1 Never abandon the patient even if tapering is unsuccessful—maintain the therapeutic relationship and consider long-term maintenance at the lowest effective dose. 1

When reversible benzodiazepine-induced toxicity is present, cognitive function typically improves within weeks to months after drug cessation. 1 Successful withdrawal is followed by improved psychomotor and cognitive functioning, particularly in memory and daytime alertness. 1

---

Critical Pitfalls to Avoid

1. Never calculate percentage reductions from the original dose—this causes disproportionately large final reductions. Always reduce by a percentage of the current dose. 1

2. Never taper too quickly. Research shows that even a 10% reduction every 3 days resulted in only 24% of patients completing withdrawal successfully. 1 A slower taper (10% per month) is far better tolerated. 5, 6

3. Never substitute another benzodiazepine or Z-drug (zolpidem, zaleplon) as these carry similar risks in older adults. 1

4. Do not add multiple new medications during the taper unless absolutely necessary. Focus on optimizing existing therapy and non-pharmacologic strategies. 1

5. Advise the patient of increased overdose risk if she returns to previous doses after tolerance is lost. 1 Once the taper is complete, reinitiation at the old dose can cause respiratory depression.

---

Summary Algorithm

1. Maintain paroxetine 20 mg BID throughout the taper 1
2. Add gabapentin 100–300 mg at bedtime, titrate as tolerated 1
3. Reduce alprazolam by 10% of current dose per month 1
4. Integrate CBT targeting anxiety sensitivity and avoidance 1
5. Follow up monthly, more frequently during difficult phases 1
6. Pause taper for 2–4 weeks if clinically significant withdrawal emerges 1
7. Consider low-dose doxepin 3–6 mg if insomnia becomes problematic 1
8. Refer to specialist if history of seizures, unstable comorbidities, or unsuccessful taper 1

Expected timeline: 12–18 months minimum, possibly longer. 1 The taper is successful as long as the patient is making progress—durability matters more than speed. 1